A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and Maintenance Therapy as First‐Line for HER2‐Negative Metastatic Breast Cancer

Bevacizumab in combination with taxanes in HER2‐negative metastatic breast cancer (MBC) patients has shown improved progression‐free survival (PFS), despite the lack of clear overall survival (OS) benefit. We performed a retrospective analysis to evaluate the impact of paclitaxel‐bevacizumab and of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cell Physiol
Main Authors: Gamucci, Teresa, Mentuccia, Lucia, Natoli, Clara, Sperduti, Isabella, Cassano, Alessandra, Michelotti, Andrea, Di Lauro, Luigi, Sergi, Domenico, Fabi, Alessandra, Sarobba, Maria G., Marchetti, Paolo, Barba, Maddalena, Magnolfi, Emanuela, Maugeri‐Saccà, Marcello, Rossi, Ernesto, Sini, Valentina, Grassadonia, Antonino, Pellegrini, Domenica, Astone, Antonino, Nisticò, Cecilia, Angelini, Franco, Vaccaro, Angela, Pellegrino, Arianna, De Angelis, Claudia, Palleschi, Michela, Moscetti, Luca, Bertolini, Ilaria, Buglioni, Simonetta, Giordano, Antonio, Pizzuti, Laura, Vici, Patrizia
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6220933/
https://ncbi.nlm.nih.gov/pubmed/27861874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcp.25685
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados